[ad_1]
Grandbrothers
Rezolute (NASDAQ:RZLT) stated it has acquired FDA clearance of its Investigational New Drug utility for a Part 3 registrational research of its drug RZ358, or ersodetug, for the therapy of hypoglycemia in sufferers with tumor hyperinsulinism, or HI.
The corporate plans to start enrollment for the trial within the first half of 2025.
Ersodetug can be in Part 3 testing in sufferers with congenital HI, with topline knowledge anticipated in mid-2025, in response to an announcement.
[ad_2]
Source link
